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ABSTRAK
Nodul tiroid sangat umum diketemukan. Walaupun banyak kasus nodul tiroid yang didapati dari pemeriksan 
fisik, ternyata banyak juga yang diketemukan secara tidak sengaja pada saat pemeriksaan radiologi. Sepuluh 
sampai 15% dari nodul tiroid merupakan keganasan tiroid. Klinisi seperti internis/endokrinologis bertugas 
mengklasifikasikan nodul tersebut, menstratifikasikan risiko karsinoma tiroid, melakukan upaya diagnostik, 
memberikan terapi medis / non-bedah, memilah kasus yang memerlukan operasi dan melakukan follow-up 
jangka panjang. Artikel ini merupakan ulasan terkini dari upaya diagnostik dan terapi nodul tiroid, fokus 
pada algoritme penatalaksaan nodul tiroid dan karsinoma tiroid berdiferensiasi baik dari American Thyroid 
Association yang terbaru.
Kata kunci: nodul tiroid, karsinoma tiroid, penatalaksanaan, terapi.
ABSTRACT
Thyroid nodules are frequently found. Although they are often palpable, many are found incidentally during 
unrelated radiographic studies. Ten to 15% of thyroid nodules represents thyroid malignancy. Clinician suc as an 
internist/endocrinologist have to  classify the nodule, stratify the risk of thyroid cancer, performed a diagnostic 
work-up, provide medical / non-surgical therapy, select candidates for surgery and provide appropriate follow-
up that should last a lifetime. This article provide an up-date review of diagnostic approach and management 
of thyroid nodules, focusing on current algorithm in lights of the most recent published American Thyroid 
Association thyroid nodule and differentiated thyroid cancer management guidelines.
Keywords: thyroid nodule, thyroid cancer, management, therapy.
INTRODUCTION
Nodules in the thyroid gland, whether 
solitary or multiple, are very common in 
clinical practice. Thyroid nodules are detected 
in approximately 5-7% of an adult population 
upon physical examination. Since modern 
ultrasound (US) techniques can detect small 
nodules, the frequency of thyroid nodules has 
been reported as high as 67% in unselected 
subjects.1 Furthermore, thyroid nodules continue 
to be diagnosed with great frequency, probably 
because of widespread use of various imaging 
procedures (computed tomography (CT) 
scan, magnetic resonance imaging (MRI), 
positron emission tomography (PET), etc.) that 
detect thyroid nodules “incidentally”.2 Thyroid 
nodules are clinically important because they 
can represents thyroid cancer, which occurs 
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approximately 10-15% of nodules.3 Other 
consideration are the risk of thyroid dysfunction 
(autonomous adenoma and toxic multinodular 
goiter), compressive symptoms and some 
cosmetic concern. The main concern of patients 
and physicians is to diagnosed the suspected 
cancers as rapidly and cost effectively as possible 
and reduce unnecessary thyroid surgery.4
This article reviews the current thinking 
regarding work up of de novo thyroid nodule. 
We highlight the most recent 2015 publication 
of the American Thyroid Association’s (ATA) 
management guidelines on thyroid nodules and 
differentiated thyroid cancer.5
ETIOLOGY OF THYROID NODULES
As defined by the ATA’s task force on 
the management of thyroid nodules and 
differentiated thyroid cancer,5 a thyroid nodule 
can defined as a discrete lesion within the thyroid 
gland that is radiologically distinct from the 
surrounding parenchyma. It may be solitary, 
multiple, cystic, or solid, and may or not be 
functional; accordingly, the exact morphological 
characteristics, thyroid functional status and 
pathological evaluation need to be assessed.6 
A simple way to classify thyroid nodules is to 
describe them as non-neoplastic and neoplastic. 
Neoplastic thyroid nodules can be benign or 
malignant.7 The differential diagnosis of the 
thyroid nodule are listed in Table 1.
DIAGNOSIS APPROACH OF THYROID 
NODULES: THYROID CANCER OR NOT?
The most important point in the diagnostic 
approach is to look for data indicating malignancy 
in the findings obtained through the patient’s 
history, physical examination, laboratory test, 
and imaging techniques (Table 2).8 There are 
four essential modalities: clinical evaluation, 
thyroid function test, thyroid US, the FNA,4,9 
and they will be discussed briefly.
Clinical Examination
Most thyroid nodules are asymptomatic and 
discovered by the patient or by physician during 
neck palpation. The features (sign and symptoms) 
of thyroid malignancy are shown in Table 3 that 
can be found in various settings, including during 





 - Compensatory after partial thyroidectomy
 - Inflammatory
 - Acute bacterial thyroiditis
 - Subacute thyroiditis
 - Lymphocytic (Hashimoto’s) thyroiditis
Benign neoplasms
 - Non-functioning (cold nodules)
 - Solid (or mixed): adenoma
 - Cystic
 - Functioning (hot nodules)
 - Adenoma
Malignant neoplasms
 - Primary carcinoma
 - Papillary carcinoma
 - Follicular carcinoma
 - Anaplastic carcinoma
 - Medullary carcinoma
 - Thyroid lymphoma
 - Thyroid metastasis from other primaries
Table 2. Diagnostic methods used in the evaluation of 
thyroid nodule
Clinical examination
 - History of benign thyroid disease
 - History of head and neck irradiation
 - Family history of thyroid cancer
 - Physical examination
Laboratory investigations
 - TSH
 - Anti-TPO/anti-Tg antibody
 - Serum calcitonin (selected cases)
Imaging methods
 - Thyroid ultrasonography
 - Radionuclide scanning (selective use)
 - CT, MRI, PET scan (selective use)
Cytologic or histologic examination
 - Fine-needle aspiration
 - Large-needle biopsy
 - Core-needle biopsy
Abbreviations: TSH, thyroid stimulating hormone; 
Anti-TPO, antibody antithyroglobulin antibody; Anti-Tg, 
antithyroglobulin antibody; CT, compute tomography; 
MRI, magnetic resonance imaging; PET, positron 
emission tomography
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routine physical examination or nodule found 
incidentally on imaging procedure.5,9,10
Laboratory Investigations
Thyroid Stimulating Hormone (TSH) – 
thyroid peroxidase antibodies. After obtaining 
a history and physical examination, a decision 
will be made about whether to further pursue 
workup. The first step, if that workup is to 
be undertaken, is to obtain a result of TSH.5 
A finding of suppressed TSH concentration 
suggest the need for determination of serum 
free thyroxine (fT4) and free triidothyronine 
(fT3)4,6,11 and thyroid scintigraphy (if available) 
to visualize areas of high (hot nodules) and 
low (cold nodules) iodine uptake.5 Functioning 
nodules has little possibility of being malignant; 
hence, no additional cytologic evaluation is 
necessary except in context of multiple thyroid 
nodules.6 In cases of normal or high serum TSH, 
diagnostic US should be performed. A normal 
TSH should be followed by needle-biopsy if 
appropriate, and a high TSH should get a work-
up for hypothyroidism (anti thyroid peroxidase 
antibodies should also be obtained to confirm 
Hashimoto’s thyroiditis) in addition to needle 
biopsy when indicated.5,11
Other laboratory: Antithyroglobulin and 
calcitonin. The essential of thyroglobulin 
combined with anti-thyroglobulin antibody 
titering as they are markers for recurrence 
of disease in the follow-up of thyroid cancer 
after total thyroidectomy and radioactive 
ablation therapy.4,9-11 Measurement of antithyroid 
antibody testing (anti-thyroid peroxidase and 
anti-thyroglobulin) is not necessary in the routine 
work-up of a thyroid nodule.5 One additional 
study that merits mentioning is calcitonin. 
Calcitonin is a sensitive and specific tumor 
marker used in the diagnosis, surveillance, 
and prognosis of medullary thyroid carcinoma 
(MTC).11 In the presence of a family history 
of medullary carcinoma or multiple endocrine 
neoplasia syndromes, the presence of nodule 
should alert the possibility of MTC, thus allow 
early radical surgery. Routine serum calcitonin 
titering is not recommended in the ATA’s 
guidelines.5
Imaging Methods
Neck palpation is very imprecise with 
regard to the determination of thyroid nodule 
morphology and size.3,6,9,10 For this reason, 
imaging methods are increasingly used, although 
no imaging methods can accurately differentiate 
benign and malignant nodules. To some extent, 
morphological characterization including thyroid 
cancer risk stratification of the lesion lies on 
imaging modalities.5,8
Tabel 3. Features suggestive of increased potential of malignancy in patient with thyroid nodule
Patient history or 
characteristics Physical examination
Findings seen on imaging  
(in case of incidentaloma)
Family history of MEN, 
MTC, and PTC
Firm nodule
Nodule fixed to adjacent structures
Suspicious ultrasound features: microcalcification, 
intranodal hypervascularity (evaluated by Doppler), 
hypoechogenicity, nodule with irregular border, etc.
History of head and 
neck irradiation
Large nodules (> 4cm) Cervical lymphadenopathy
History of Hodgkin and 
non-Hodgkin lymphoma
Growth of nodule, especially during 
L-thyroxine therapy suppression 
therapy
Focal uptake on 18FDG-PET scan or 99mTcMIBI
Age < 20 or > 70 years Symptoms of compression: 
hoarseness, dysphagia, 
dysphonia, dyspnea, cough
Male sex Abnormal cervical lymphadenopathy
Paralysis of vocal cords
Abbreviations: MEN, multiple endocrine neoplasia; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; 18FDG-
PET, 18F-fluorodeoxyglucose positron emission tomography; 99mTcMIBI, 99mTc-2-methoxy-isobutylisonitrile. Source: 
Popoveniuc G and Jonklaas J. Med Clin North Am 2012
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Ultrasonography (US). US examination is 
highly accurate and sensitive in evaluating 
thyroid nodules.5,12,13 US examination was able 
to detect thyroid incidentaloma which cannot be 
obtained by physical examination. Thyroid US 
is the first choice of imaging studies for thyroid 
gland evaluation. Indication of US examination 
on thyroid nodules are: a) all types of thyroid 
nodules, b) thyroid nodules with the history 
of neck radiation, and c) thyroid nodules with 
the history of familial thyroid cancer, multiple 
endocrine neoplasia (MEN) type 2, even if the 
gland appears normal by palpation.5 Several 
ultrasound findings have been found to be 
associated with malignancy among patients 
brought to surgery after FNA. A solid nodule, 
hypoechogenicity, microcalcifications, irregular 
contours, subcapsular localization, invasive 
growth, multifocal lesion, increased nodule 
blood flow on Doppler (when TSH is normal) 
and suspicious regional lymphadenopathy on US 
indicate malignancy.14 A ratio of the anteroposterior 
diameter of the nodule to the transverse diameter 
(AP/T) >1 indicated malignancy.11 Nodules that 
are cystic, isoechoic, have regular boundaries, lack 
calcification and show no invasive growth usually 
considered benign.13
The number of nodules and their size are not 
predictive of malignancy, as a nodule smaller 
than 1 cm is as likely as a larger nodule to harbor 
neoplastic cells in the presence of suspicious US 
features. The ATA 2015 recommendation suggest 
nodules as small as 1 cm might be biopsied and 
should be followed based on risk factors (Table 
4).5 Large nodules also merit discussion; some 
nodules are so large it has been asserted that they 
should be surgically removed without taking 
the extra step of biopsy. In an article published 
in 2007,15 among patients brought to surgery 
who had been diagnosed with nodules greater 
than 4 cm, FNA results were frequently false 
negative. They often eventually affect speech 
and swallow function due to size, and for this 
reason, large nodules (~4 cm or greater) could 
be offered for surgical intervention because they 
are less accurately assessed by FNA.
Table 4. Recommended size thresholds for consideration of FNA as part of evaluation of a thyroid nodule.5
Nodule sonographic or clinical features Nodule threshold size for FNA Grade of Recommendationa
High-risk historyb
 - Nodule WITH suspicious US featuresc ≥ 1 cm A
 - Nodule WITHOUT suspicious US featuresc ≥ 1 cm I
Abnormal cervical lymph nodes Alld A
Microcalcifications present in nodule ≥ 1 cm B
Solid nodule
 - AND hypoechoic > 1 cm B
 - AND iso- or hyperechoic ≥ 1-1.5 cm C
Mixed cystic-solid nodule
 - WITH any suspicious US featuresc ≥ 1.5-2.0 cm B
 - WITHOUT any suspicious US featuresc ≥ 2.0 cm C
Spongiform nodule ≥ 2.0 cm C
Purely cystic nodule FNAC not indicatede E
a Explanation for recommendation: A, strongly recommends based on good evidence; B, recommends, based of 
fair evidence; C, recommends, based on expert opinion; E, recommends against based on fair evidence; I, neither 
recommends nor against, evidence insufficient.
b High-risk history: History of thyroid cancer in first degree relative, history of external beam radiation, exposure to ionizing 
radiation, prior hemithyroidectomy with discovery of thyroid cancer, 18FDG avidity on PET scanning, MEN2/FMTC-
associated RET proto-oncogene mutation, calcitonin >100 pg/mL.
c Suspicious features: see ultrasonography section of this issue.
d FNA cytology may be obtained from the abnormal lymph node in lieu of the thyroid nodule.
e Unless indicated as therapeutic modality.
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Thyroid Scintigraphy. Scintigraphy of the thyroid 
gland utilize one of the radioisotopes of iodine 
(usually 123I) or technetium-99 pertechnetate 
(99Tc).3-6,9,10 Its use is recommended in patients 
with suppressed TSH to document whether 
a nodule is functioning or not, before needle 
biopsy.16 Accordingly, a nodule is considered 
functioning or “hot” (i.e. has tracer uptake 
greater than the surrounding normal thyroid), 
isofunctioning or “warm” (i.e. has tracer uptake 
equal to the surrounding thyroid), and non-
functioning or “cold” (i.e. has uptake less than 
the surrounding thyroid tissue). Scintigraphy 
provides functional rather than morphological 
information, contrary to US.17 Scintigraphy has 
been largely replaced by US but still has at least 
2 roles: identifying hyperfunctioning nodules 
when a low TSH is found on initial testing, 
and to a limited extent, determining which 
nodule(s) to sample in patients with multiple 
nodules.6,16,17 Hot nodules do not require FNA, 
as they rarely harbor cancer.6,16 It is the cold 
nodule that warrants FNA, depending on size 
and US characteristics. For the purpose of biopsy 
decisions, indeterminate nodules should be 
treated as though they are nonfunctioning, and 
subjects to cytological analysis.5,16
Cytology and Histology Examination
Fine-needle aspiration and its indication. This 
is the most important study, which should never 
be left out in the presence of a thyroid nodule. 
There are 3 main considerations to categorizing 
and determining whether the nodule should 
undergo FNA: patient’s history, nodule size, 
and US features (Table 2, ATA guidelines for 
FNA threshold).5 In the context of a palpable 
nodule, FNA may be performed with or without 
US guidance.18 It is suggested that US-FNA be 
performed in: 1) nonpalpable nodules larger than 
1 cm, 2) palpable nodule smaller than 1.5 cm, 
3) deeply found nodules, 4) nodules in close to 
blood vessels, 5) nodules after a nondiagnostic 
conventional FNAC, 6) cystic or mixed nodules, 
especially if a previous conventional FNA was 
nondiagnostic, and 7) coexistence of nonpalpable 
lymphadenopathy. For nodules fall outside the 
criteria for biopsy, it is reasonable to do interval 
thyroid US follow-up.5
MANAGEMENT APPROACH
Despite many investigation options available 
to the clinicians, the management of thyroid 
nodule essentially depends on the FNA results.5 
The possible reports are benign, malignant, 
suspicious malignancy, atypia of undetermined 
significance or follicular lesion of undetermined 
significance (AUS/FLUS), follicular neoplasm 
or suspisious for a follicular neoplasm (FN/
SFN), and non-diagnostic.19 Beside cytological 
diagnosis, the treatment plan may depend on the 
patient’s age and gender and the characteristics 
of the nodule (size, consistency, activity, and 
number), and whether it is functioning or not 
(Figure 1).4,5,9,10 Treatment modalities are shown 
in Table 5.
Asymptomatic benign euthyroid  nodules 
need only watchful follow-up with annual or 
biannual US and TSH testing.5 Nevertheless, 
on some occasion, benign thyroid nodules do 
require therapeutic intervention, especially when 
they grow large and when they cause obstructive 
symptoms.3,7,10,20 Any type of malignancy, or 
when malignancy cannot be ruled out, indicated 
the need for surgical resection. The extent of 
surgery depends on the type of tumor. Simple 
hemithyroidectomy may be recommended as 
the initial step for follicular neoplasm or as 
the definitive treatment for a small, isolated 
papillary carcinoma if no other risk factors are 
present.20 All other thyroid malignancy deserve 
total thyroidectomy with complementary 
local node resection. If the histology of the 
follicular neoplasm confirms the presence of 
carcinoma, the a total thyroidectomy should be 
completed.5,7,20
Surgical Management of Thyroid Nodules
When there is malignant or suspicious 
cytologic features and/or symptoms due to 
the nodule, surgery is often recommended, 
especially for younger patients and in case in 
which there are large nodules.8 The preferred 
operation is a unilateral removal of the affected 
node.5,7,20 Complications include temporary 
and permanent unilateral vocal cord paralysis 
(1-2 and 0.5-1.0%, respectively), temporary 
and permanent hypocalcemia (1.0 and 0.5%, 
respectively), and hematomas and infections 
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(0.5 and 0.3%, respectively).7 The risk of 
complications increases with the extent of 
operation. In the patient with normal thyroid 
function postoperatively, there is no indication 
for routine L-thyroxine treatment since this does 
not seem to hinder thyroid growth in the long 
term, at least in iodine-sufficient regions.20,21 
Although an option, surgery is rarely used in 
the hyperthyroid patient with a toxic nodule. 
Radioactive iodine treatment is the preferred 
treatment for “hot” nodule.4,6
Benign cytology: Surgical treatment is 
indicated for some benign lesions, either single 
or associated with multinodular goiter, if they 
are large (>4 cm in diameter), presence of 
signs and symptoms of compression, cause 
discomfort, if there are cosmetic concern.20 
Recurrent cyst after therapeutic aspirations of the 
fluid may have indication for surgery becausae 
these lesion may have malignant cells in up to 
10% of cases. All the other benign nodules are 
candidate for medical therapy.21 The patients 
with benign cytology and low risk factors may 
still need follow up for a further 12 – 24 months 
considering 5% false negative FNA results. 
US-FNA need to be repeated if nodule grows 
significantly. Growth of nodule is considered 
significant with an increase in diameter of 20% or 
more with a minimum increase of 2 mm.5 Benign 
cytology in a patient with high risk factors as 
mentioned in Table 3 may need diagnostic 
lobectomy. Patients with a dominant nodule 
in a multi nodular goiter with compressive 
symptoms need total thyroidectomy and post-
operative L-thyroxine replacement therapy. The 
other indication for surgery in benign thyroid 
nodules include the presence of a toxic adenoma 
or a toxic multinodular goiter.9,10,20 In the event 
of thyrotoxicosis, surgery must be performed 
after restoration of a normal thyroid function by 
Figure 1. Algorithm for evaluation and treament of thyroid nodules. Source: Burman KD and Wartofsky 
L. N Engl J Med 2015. * Molecular abnormalities are not subjects of this article.
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adequate preparation with antithyroid drugs to 
avoid thyroid crisis complication.4
Malignant Cytology
In malignant cytology or suspicious cases, 
total thyroidectomy is the treatment of choice to 
achieve loco-regional control in most patients. 
This also enables a patient with thyroid cancer 
to undertake post-operative radioiodine (I131) 
ablation, to treat the microscopic disease.8,20,22 
The only exception could be a papillary 
microcarcinoma (<1 cm) of thyroid in the 
absence of local invasion. In this situation, the 
ATA suggest lobectomy.5 This article focuses on 
the investigation and treatment of thyroid nodule, 
and therefore, detailed analysis of treatment of 
all thyroid cancer is beyond the scope of our 
discussion. However, general management 
guideline of differentiated thyroid cancer is 
outlined below.
Papillary thyroid carcinoma (PTC) is the 
most common thyroid cancer accounting for 
80–85% of thyroid cancers.3,7-10 It is associated 
with good prognosis and the cancers more than 1 
cm are best managed with total thyroidectomy.5,8 
Completion thyroidectomy is indicated in 
patients who undergone prior diagnostic 
Table 5. Advantages and disadvantages of the established treatment options for the thyoid nodule
Treatment Advantages Disadvantages
Levothyroxine Outpatient Low efficiency
Low cost Lifelong treatment
May slow nodule growth Regrowth after cassation
Possibly prevents new nodule formation Adverse effects on bone and heart
Not feasible with TSH suppressed
Radioiodine Outpatient Operator dependency
Low cost Contraseptives needed in fertile women
Side effect
 - Radiation thyroiditis
 - Graves’ disease
 - Hypothyroidism
 - Long-term cancer risk unknown
Ethanol injection Outpatient Repeat injection needed




 - Transient dysphonia
 - Thyroiditis
 - Extranodular fibrosis
 - Complicates subsequent cytological interpretation
Surgery Prompt relief of symptoms Inpatient
Nodule abplation High cost
Definite diagnosis Anesthesiological risk
Surgical risk
 - Vocal cord paralysis
 - Hypoparathyroidism
 - Hypothyroidism
 - Bleeding and infection
 - Scar
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lobectomy and are found on final pathology 
to have PTC that is larger than 1 cm.23 The 
completion of thyroidectomy should generally 
performed within 6 months of the original 
procedure in order to minimize the risk of lymph 
node metastasis. Routine central compartment 
dissection is controversial, but it is estimated 
that up to 50% of patients have neck metastasis 
at the time of diagnosis.24 Currently, there is 
no prospective, randomized trials comparing 
prophylactic to therapeutic central lymph node 
dissection. Current practice guidelines from the 
ATA recommend therapeutic central or lateral 
lymph node clearance in PTC for clinically 
positive nodes. But guidelines regarding 
prophylactic neck dissection are less clear. The 
prophylactic neck dissection may be performed 
parpticularly in patients with T3 or T4 tumors, 
and dissection “may be reasonably avoided” 
for patients with T1 or T2 disease.5 Currently, 
lifelong TSH suppression is advocated though 
the degree of suppression and its length are the 
subjects of review.8,23
Follicular thyroid cancer (FTC) are diagnosed 
on histology based on capsular/vascular invasion 
and constitute 10% of thyroid malignancy.3,7-10 
Routine FNA cytology are generally not able 
to be discerned this histologic features from 
follicular neoplasm (their benign counterpart). 
Thus, AUS/FLUS and FN/SFN need diagnostic 
lobectomy to confirm follicular carcinoma.9,19,20 
If this is proven on histology, the patient needs 
completion thyroidectomy later.5,22 The role of 
intra-operative frozen section of thyroid these 
patients generates considerable controversies. 
A study involving 564 patients with thyroid 
tumors examined the frozen section in 70% of the 
patients. Based on this study, it was concluded 
that intra-operative frozen section on thyroid 
tumors adds very little to surgical management.25 
Follicular cancer spreads hematogenously as 
compared to PTC which mainly spreads by the 
lymphatic system. Therefore routine central 
compartment clearance is not indicated unless 
there are positive neck nodes on US and FNA. 
Radioactive I131 ablation and lifelong TSH 
suppression therapy with follow-up as for PTC 
is required.8,23 Post-operative treatment with 
radioactive I131 is primarily applied for  three 
reasons. First, RAI ablates or eliminates any 
remaining normal thyroid tissue and facilitates 
the specificity of thyroglobulin as a tumor 
markers in long-term surveillance. Second, RAI 
serves as an adjuvant treatment of intermediate-
risk patients to destroy the remaining occult 
small foci of well-differentiated thyroid 
carcinoma and potentiating a decrease in risk of 
recurrence. Finnaly, RAI may be administered in 
a therapeutic fashion for those high-risk patients 
with macroscopic residual disease (remnant 
ablation) or distant metastatic disease.22,23 
The 2015 ATA recommendation currently 
recommends the use of RAI postoperatively in 
patients with T3, T4, or M1 disease.5
Nonsurgical Management of Thyroid Nodules
Levothyroxine therapy. Although on the 
decline, it is still common practice to used thyroid 
suppression with levothyroxine (L-thyroxine) 
in the management of solid thyroid nodule 
in euthyroid patients.26 The aim is to shrink 
existing nodules, considered to be a favorable 
sign indicating that the nodule is benign.3 
However, the effectiveness of medical treatment 
of benign nodule(s) with L-TSH suppressive 
doses remains controversial.5 It seems that 
young healthy patients with small and solid 
nodules from iodine-deficient areas could 
benefit the most.21 Approximately 20% of 
solitary solid nodules actually regress as a 
result of L-thyroxine therapy, and cessation of 
therapy leads to rapid regrowth. On average, 
long-term therapy is without significant nodule-
reducing effect. Growth can be suppressed 
or slowed, and the formation of new nodules 
may be prevented. However, this necessitates 
that serum TSH is suppressed to subnormal 
values (treat to TSH target 0.1 – 0.45 mIU/mL), 
which may have adverse effects.21 This degree 
of TSH suppression, called mild or subclinical 
hyperthyroidism, is associated with an increased 
risk of atrial fibrillation, other cardiac side 
effects, and reduced bone density, potentially 
leading to osteoporosis.26 The use of L-thyroxine 
therapy should be avoided for large nodule or 
long standing goiters, particularly of the TSH 
value is less than 0.5 mIU/mL, postmenopausal 
women or person older than 60 years, patients 
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who have osteoporosis, cardiovascular disease or 
systemic illnesses.21,26 Also, L-thyroxine therapy 
has no effect in the cystic nodule and in patients 
with spontaneously low serum TSH with or 
without elevated thyroid hormone levels.21 For 
these reasons, its use is questionable; at most, 
it can be used in younger patients with small 
nodules, in whom treatment is least necessary. 
Routine L-thyroxine suppressive therapy is no 
longer recommended for cytologically benign 
nodules.5
Radioactive iodine. If the patient has 
hyperthyroidism (toxic nodule), antithyroid 
drugs (propylthiouracyl or methimazole) can 
normalize thyroid function but disease recurrence 
is the rule when medication is stopped.4 With 
the exception of few patients who have a large 
nodule, in which case that surgery indicated, 
radioactive iodine is the treatment of choice. 
This is also the case for the clinically euthyroid 
patient with functioning (“hot”) nodule, in 
whom treatment may be dictated by the nodule 
size, which may cause compression or cosmetic 
disturbance.6 In addition, radioactive iodine 
treatment is used to prevent hyperthyroidism 
(annual risk of approximately 4%). Pretreatment 
with recombinant human TSH offers the 
prospect that radioiodine treatment of nontoxic 
nodular goiters can be simplified and improved, 
however, more information about this strategy 
is needed.27 A cure rate (i.e. normalization of 
thyroid function and the appearance on a thyroid 
isotope scintigraphy) of 70% is seen, and the 
nodule shrinks 30-60% following a single dose 
of radioactive iodine.22 Side effects are few, with 
rare cases of radiation thyroiditis and transition 
to Graves’ disease. The risk of hypothyroidism 
is approximately 10% after 5 years and unrelated 
to the dose of radioactivity.27 The long-term 
risk of malignancy is unknown but considered 
negligible. Radioactive iodine has no effect 
on the nonfunctioning (cold) nodule, whether 
solid or cystic. In the future, the possibility 
of stimulation with recombinant human TSH 
before radioactive iodine treatment may lead to 
an increased iodine uptake and also lead to an 
increased iodine uptake and also an effect in the 
solid and cold nodule.22
In Situ Destruction of Thyroid Nodules
Percutaneous Ethanol Injection (PEI). 
US-guided PEI into nodules (especially the 
symptomatic cystic nodules) has been proposed 
as a valid, safe, well tolerated, inexpensive 
alternative therapputic method for in situ 
ablation of benign thyroid nodule.21 Ethanol 
(70-100%) causes local small vessel thrombosis 
and coagulative necrosis, leading to fibrosis and 
permanent tissue ablation. It has been used both 
autonomously functioning thyroid nodules and 
nonfunctioning thyroid  nodules, whether solid 
or cystic. In solitary nodule, nonfunctioning 
thyroid nodules, approximately 50% of patients 
are relieved of their clinical symptoms based on 
a 50-90% nodule volume reduction in thyroid 
nodules larger than 30 gr. Additional injections 
have little effect.28 It is an option for patients who 
do not wish to undergo radioiodine treatment or 
surgery.5 However, it often necessitates repeat 
treatment to obtain complete cure. However, 
because of the frequent,  although transient, side 
effects (particularly local pain), PEI should be 
limited to highly selected nodules that are easily 
accessible to palpation in patients refusing I131 
and surgery.5,21 This procedure, often used in 
Italian centers, is not a routine option, should still 
be classified as experimental, and requires the 
special technical skill that can be obtained only at 
center familiar with interventional ultrasound.29
Intertitial Laser Photocoagulation (IL). 
Ultrasound-guided ILP has been used as a 
norsurgical alternative in the treatment of benign, 
solitary, solid (both “hot” or “cold” nodule) 
in patients who cannot (or will not) undergo 
surgery.30 One treatment lasting approximately 
10 min resulted in a 40% nodule reduction and 
significant pressure symptoms reduction. These 
results are similar to those obtained using ethanol 
therapy. The fact that the spread of energy with 
a laser (thermal destruction) can be controlled, 
as opposed to chemical destruction by injection 
of ethanol, may favor laser therapy in then long-
term.21
Radiofrequency ablation. Radiofrequency 
ablation (RFA) is a minimally invasive treatment 
for certain type of benign thyroid nodules 
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when surgery is not an option. RFA therapy 
has mainly been aimed at decreasing pressure 
symptoms, improving cosmetic results as well 
as resolving thyrotoxic status in “hot” nodules. 
For “cold” nodules, the efficacy of RFA has 
mainly been evaluated in terms of reduction 
of nodule volume, pressure symptoms, and 
cosmetic symptoms.31 A recent study by Korean 
group32 who compared the efficacy and safety of 
surgery and RFA reported that both are effective 
treatment in benign thyroid nodules. After 
RAI, the nodal volume decreased significantly 
and give more benefit in terms of lesser 
post-operative complication, preservation of 
thyroid function and fewer hospitalization days, 
compared to surgery. Currently, no explanation 
how international guidelines recommends RFA 
for benign thyoid nodule.5
FOLLOW-UP
The follow-up of benign euthyroid thyroid 
nodules depends on the clinical, US and 
cytological characteristics described earlier.5 
Usually, thyroid nodule require reevaluation every 
12 to 24 months by clinical assessment (history 
and physical examination), US and TSH. Nodules 
that have been cytologically labeled as inadequate, 
inconclusive or indeterminate may need more 
careful monitoring and repeat biopsies within 1 
to 2 months.10 Substantial growth detected by US 
(defined as an enlargement of more than 20% or 
more than 2 mm) does not necessarily indicate 
malignancy because benign lesion also grow 
larger, but a repeat FNA should be considered. The 
same recommendation is valid if new clinical or US 
features of malignancy appear.5,9 Thyroglobulin 
level monitoring is used a screen for cancer 
recurrence in patients with differentiated thyroid 
cancer after total thyroidectomy and radioactive 
iodine ablation.5,7 Thyroid function should also 
be regularly investigated (usualy yearly) in those 
patients who have been treated with ablative 
options (surgery or I131).23 This is generally 
evaluated by a serum TSH determination. If 
hypothyroidism shows up, treatment should be 
started with L-thyroxine replacement therapy, 
which itself also requires annual follow-up. Post-
surgical thyroid US is useful in monitoring the 
evolution of the remaining gland.
CONCLUSION
Diagnosis and therapy of thyroid nodules is 
highly determinate by early evaluation, clinical 
criteria using TSH measurement, US and FNA 
as initial test. They should be practical, efficient 
and cost-effective. In multinodular thyroid, 
FNA biopsy can be restricted to the dominant 
nodule with special preference to high suspicious 
pattern nodule on imaging. Surgery is required 
if malignant or suspicious cytology is reported. 
Rapid growth and increasing pressure effects 
and cosmetic reason are also indication for 
surgery. Simple observation and L-thyroxine 
suppression are acceptable management option 
with presumably benign thyroid nodules. 
Ablation of thyroid nodules (ethanol injection 
and laser photocoagulation) have been used 
for in situ destruction of benign solid nodules. 
Radiofrequency ablation (RFA) therapy is 
currently viewed as experimental therapeutic 
method. Radioiodine therapy (RAI)  may be 
used for the management in selected patients. 
For indeterminate cytology, diagnostic surgery 
may needed to exclude malignancy.
Declaration of interest: The author declare 
that there is no conflict of interest that would 
prejudice the impartiality of this scientific work.
REFERENCES
1. Dean DS, Gharib H. Epidemiology of thyroid nodules. 
Best Pract Res Clin Endocrinol Metab. 2008;22:901–
11.
2. Davies L, Ouellette M, Hunter M, Welch G. The 
increasing incidence of small thyroid cancers: 
where are the cases coming from? Laringoscope. 
2010;120:2446-51.
3. Mazzaferri EL. Management of a solitary thyroid 
nodule. New Engl J Med. 1993;328:553–9.
4. Djokomoeljanto R. Kelainan kelenjar tiroid: fokus 
pada terapi penyakit Graves dan nodul tiroid. In: 
Pengelolaan secara rasional dan terkini di bidang 
endokrinologi. National Symposium of Indonesian 
Society of Endocrinology. Padang: West Sumatra 
branch of Indonesian Society of Endocrinology; 2004. 
p. 32–57.
5. Haugen BR, Alexander EK, Bible KC, et al. American 
Thyroid Association management guidelines for adults 
patients with thyroid nodules and differentiated thyroid 
cancer. Thyroid. 2016;26:1–133.
6. Pemayun TGD. Asesmen nodul tiroid. In: Hardiman 
D, Kartodarsono S, Pramana TY, Sugiarto, eds. 
Proceeding book of tenth Annual Scientific Meeting 
Vol 48 • Number 3 • July 2016                                              Current diagnosis and management of thyroid nodules
257
of PERKENI Joglosemar. Solo: PERKENI; 2009. p. 
271–80.
7. Shchlumberger M, Pacini F. Thyroid tumors. Nucleon; 
Paris. 2006.
8. Masjhur JS. Karsinoma tiroid. In: Djokomoeljanto R, 
ed. Buku ajar tiroidologi klinik. Semarang: Diponegoro 
University Press; 2007. p. 193–216.
9. Burman KD, Wartofsky L. Thyroid nodules. New Engl 
J Med. 2015;373:2347–56.
10. Gharib H, Papini E. Thyroid nodules: clinical 
importance, assessment, and treatment. Endocrinol 
Metab Clin North Am. 2007;36:707–35.
11. Ladenson PW. Optimal laboratory testing for diagnosis 
and monitoring of thyroid nodules, goiter, and thyroid 
cancer. Clin Chem. 1996;42:183–7.
12. Henrichsen TL, Reading CC. Thyroid ultrasonography. 
Part 2: Nodules. Radiol Clin North Am. 2011;49:417–
24.
13. Moon WJ, Baek JH, Jung SL, et al. Ultrasonography 
and the ultrasound-based management of thyroid 
nodules. Korean J Radiol. 2011;12:1–14. DOI: 
10.3348/kjr.2011.12.1.1.
14. Nam-Goong IS,  Kim HY,  Gong G,  e t  a l . 
Ultrasonography-guided fine-needle aspiration of 
thyroid incidentaloma: correlation with pathological 
findings. Clin Endocrinol. 2004;60:21–8.
15. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty 
SE, Yim JH. The incidence of cancer and rate of false-
negative cytology in thyroid nodules greater than or 
equal to 4 cm in size. Surgery. 2007;142:837–44.
16. Ashcraft MW, van Herle AJ. Management of thyroid 
nodules. II. Scanning techniques, thyroid suppressive 
therapy, and fine needle aspiration. Head Neck Surg. 
1981;3:297–322.
17. Giuffrida D, Gharib H. Controversies in the 
management of cold, hot, and occult thyroid nodules. 
Am J Med. 1995;99:642–50.
18. Cibas ES, Alexander EK, Benson CM, et al. Indications 
for thyroid FNA and pre-FNA requirements: a synopsis 
of the National Cancer Institute Thyroid Fine-Needle 
Aspiration State of the Science Conference. Diag 
Cytopathol. 2008;36:390–9.
19. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic 
terminology and morphologic criteria for cytologic 
diagnosis of thyroid lesions: a synopsis of the National 
Cancer Institute Thyroid Fine-Needle Aspiration State 
of the Science Conference. Diagn Cytopathol. 2008; 
36:425–37.
20. Sakarofas GH, Peros G. Thyroid nodule: a potential 
malignant lesion; optimal management from a surgical 
perspective. Cancer Treat Rev. 2006;32:191–202.
21. Subekti I. Manajemen non-bedah pada nodul tiroid. In: 
Pemayun TGD, Nugroho KH, Minuljo TT, Naibaho 
RM, ed. Thyroid workshop. Annual Scientific Meeting 
of Indonesian Society of Endocrinology in conjunction 
with Semarang Endocrine Metabolic Meeting. 
Semarang: PERKENI; 2016. p. 15–22.
22. Masjhur JS. Peranan kedokteran nuklir dalam 
tiroidologi. In: Djokomoeljanto R, Darmono, Suhartono 
T, Pemayun TGD, Nugroho KHS, eds. Thyroidology 
update 1. Semarang: Diponegoro University Press; 
2005. p. 97–108.
23. Yoo JY, Stang MT. Current guidelines for postoperative 
treatment and follow-up of well-differentiated thyroid 
cancer. Surg Oncol Clin North Am. 2016;25:41–59.
24. Rosenbaum MA, McHenry CR. Contemporary 
management of papillary carcinoma of the thyroid 
gland. Expert Rev Anticancer Ther. 2009;9:317–29.
25. Brooks AD, Shaha AR, DuMornay W, et al. Role 
of fine-needle aspiration biopsy and frozen section 
analysis in the surgical management of thyroid tumors. 
Ann Surg Oncol. 2001;8:92–100.
26. Gharib H, Mazzaferri EL. Thyroxine suppressive 
therapy in patients with nodular thyroid disease. Ann 
Intern Med. 1998;128:386–94.
27. Weetman AP. Radioiodine treatment for benign thyroid 
diseases. Clin Endocrinol. 2007;66:757–64.
28. Tarantino L, Francica G, Sordelli I, et al. Percutaneous 
ethanol injection of hyperfunction thyroid nodules: 
long-term follow-up in 125 patients. Am J Roentgen. 
2008;190:800–8.
29. Lippi F, Ferrari C, Manetti L, et al. treatment of solitary 
autonomous thyroid nodules by percutaneous ethanol 
injection: results form an Italian multicenter study. The 
multicenter Study Group. J Clin Endocrinol Metab. 
1996;81:3261–4.
30. Dossing H, Benndbaek FN, Karstrup S, Hegedus L. 
Benign solitary solid cold thyroid nodules: US-guided 
interstitial laser photocoagulation – initial experience. 
Radiology. 2002;225:53–7.
31. Lee MT, Wang CY. Radiofrequency ablation in nodular 
thyroid diseases. J Med Ultrasound. 2013;21:62–70.
32. Che Y, jin S, Wang L, Zhang X, Ki Y, Baek JH. 
Treatment of benign thyroid nodules: comparison of 
surgery with radiofrequency ablation. AJRN Am J 
Neuroradiol. 2015;36:1321–25.
